Merck wins FDA OK for Noxafil tablets
This article was originally published in Scrip
Executive Summary
Merck won approval from the US FDA its oral antifungal agent Noxafil (posaconazole) 100mg delayed-release tablets as a prophylaxis therapy for invasive Aspergillus and Candida infections in severely immunocompromised patients 13 years or older at high risk of developing those infections, like those who have undergone hematopoietic stem cell transplants (HSCT) and have graft-versus-host disease (GVHD), or patients with cancers of the blood who are experiencing prolonged neutropenia as a result of chemotherapy.